Advertisement

ISCT Talking with Giants Trilogy

      Alongside the International Society of Cell & Gene Therapy (ISCT), it is my privilege as Senior Editor of Cytotherapy to introduce to you this latest addition to the “Talking with Giants” series – a special “Talking with Giants” Trilogy. Celebrating the highly successful development of the first chimeric antigen receptor T cell (CAR-T) therapy, this novel immunotherapy, pioneered by the University of Pennsylvania, has shown remarkable clinical results, pushing the rapid approval of CAR-T therapies for treating pediatric and adult patients suffering from leukemia and lymphoma. This advancement has pushed, in turn, the development of personalized cellular therapies for treating both bloodborne and potentially tumorous cancers, offering new hope to many cancer patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect